Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AmpC beta-lactamase mutant sequencing

ABSTRACT: Sequencing mutant library in the E. coli beta-lactamase gene ampC selected on different drugs

PROVIDER: PRJEB36781 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3929140_1.fastq.gz	Fastqsanger.gz
	ERR3929140_2.fastq.gz	Fastqsanger.gz
	ERR3929150_1.fastq.gz	Fastqsanger.gz
	ERR3929150_2.fastq.gz	Fastqsanger.gz
	ERR3929160_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 404

Similar Datasets

Cefazolin and Imipenem Enhance AmpC Expression and Resistance in NagZ-dependent manner in Enterobacter cloacae complex

Project description:Background: Enterobacter cloacae complex (ECC) is a common opportunistic pathogen and is responsible for causing various infections in humans. Owing to its inducible chromosomal AmpC β-lactamase (AmpC), ECC is inherently resistant to the 1st- and 2nd- generation cephalosporins. However, whether β-lactams antibiotics enhance ECC resistance remains unclear. Results: In this study, we found that subinhibitory concentrations (SICs) of cefazolin (CFZ) and imipenem (IMP) can advance the expression of AmpC and enhance its resistance towards β-lactams through NagZ in Enterobacter cloacae (EC). Further, AmpC manifested a substantial upregulation in EC in response to SICs of CFZ and IMP. In nagZ knockout EC (ΔnagZ), the resistance to β-lactam antibiotics was rather weakened and the effect of CFZ and IMP on AmpC induction was completely abrogated. NagZ ectopic expression can rescue the induction effects of CFZ and IMP on AmpC and increase ΔnagZ resistance. More importantly, CFZ and IMP have the potential to induce the expression of AmpR's target genes in a NagZ-dependent manner. Conclusions: Our findings suggest that NagZ is a critical determinant for CFZ and IMP to promote AmpC expression and resistance and that CFZ and IMP should be used with caution since they may aggravate ECC resistance. At the same time, this study further improves our understanding of resistance mechanisms in ECC.

2022-07-01 | GSE207144 | GEO

LC-MS/MS analysis demonstrates a decrease in porins and increase in CMY-2-like beta-lactamases in E. coli exposed to meropenem

Project description:While ESBL and AmpC beta-lactamases barely degrade carbapenems, they are able to bind them and prevent them from interacting with penicillin binding proteins thereby preventing their effect. When these beta-lactamases are expressed at a high level and combined with a decreased influx of carbapenems due to a decrease in membrane permeability, Enterobacterales can become resistant to carbapenems. In this study we developed a LC-MS/MS assay for the detection of the E. coli porins OmpC and OmpF, it’s chromosomal AmpC beta-lactamase and the plasmid-mediated CMY-2 beta-lactamase. Subsequently, we cultured CMY-2 positive E. coli isolates in the presence of meropenem and analyzed mutants that showed increased resistance to meropenem using our developed assay and western blot. In all five selected strains, a decrease in OmpC and/or OmpF was the first event towards an increase in meropenem minimum inhibitory concentrations (MICs). Subsequently, in four of the five isolate series, MICs increased further after an increase in CMY-2-like production.

2022-04-04 | PXD025363 | Pride

Extended Spectrum Beta-Lactamase-producing Enterobacteriaceae

Project description:Extended Spectrum Beta-Lactamase-producing Enterobacteriaceae Raw sequence reads

| PRJNA476828 | ENA

AmpC-Eco

Project description:AmpC-Eco

| PRJEB61431 | ENA

First penicillin-binding protein occupancy patterns for 15 β-lactams and β-lactamase inhibitors in Mycobacterium abscessus

Project description:Mycobacterium abscessus (Mab) causes serious infections that often require over 18 months of antibiotic combination therapy. With β lactam antibiotics being safe, double β-lactam and β-lactam/β-lactamase inhibitor combinations are of interest for improving treatment of Mab infections and minimizing toxicity. However, a mechanistic approach for building these combinations is lacking since little is known about which penicillin-binding protein (PBP) target receptors are inactivated by different β-lactams in Mab. This project aimed to identify PBPs in Mab and study the binding affinities of each of these PBPs with β-lactam antibiotics. These first PBP occupancy patterns in Mab provide a mechanistic foundation for selecting and optimizing safe and effective combination therapies with β-lactams.

2020-11-24 | PXD022644 | Pride

Project description:AmpC beta-lactamase producing Klebsiella aerogenes

| PRJNA646204 | ENA

Inducible AmpC β-lactamases detected in Southeast Asian Escherichia coli and Klebsiella pneumoniae isolates

Project description:AmpC β-lactamases in SE Asian Enterobacterales

| PRJEB76280 | ENA

Horizontally-acquired AmpC (FOX-4) in Pseudomonas aeruginosa

Project description:Emergence of resistance to novel β-lactam β-lactamase inhibitor combinations due to horizontally-acquired AmpC (FOX-4) in Pseudomonas aeruginosa

| PRJEB34942 | ENA

Fecal Microbiota Transplantation for Extended-Spectrum Beta Lactamase Carriers.

Project description:Fecal Microbiota Transplantation for Extended-Spectrum Beta Lactamase Carriers.

| PRJEB46779 | ENA

Transcriptional alterations of virulence-associated genes in extended spectrum beta-lactamase (ESBL)-producing uropathogenic Escherichia coli during morphologic transitions induced by ineffective antibiotics

Project description:The present study examines changes in global gene expression patterns and in virulence factor-associated genes in an extended spectrum beta-lactamase (ESBL)-producing UPEC (ESBL019) during the morphologic transitions induced by an ineffective antibiotic and in the presence of human primary bladder epithelial cells. The morphological shifts induced by ineffective antibiotics are associated with significant transcriptional virulence alterations in ESBL-producing UPEC, which may affect survival and persistence in the urinary tract.

2017-06-06 | GSE99661 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data